FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C
August 3, 2017 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cirrhosis | Drugs & Pharmacology | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Liver | Liver Disease | Urology & Nephrology